NIAID established the Consortium of Food Allergy Research (CoFAR) in 2005 to investigate questions related to food allergies. In 2011, CoFAR opened the Eosinophilic Esophagitis Databank. This clinical study investigates the genetic components underlying development of eosinophilic esophagitis.
NIAID has partnered with the pharmaceutical company GlaxoSmithKline to evaluate the investigational asthma drug mepolizumab as a possible new treatment for people with eosinophilic granulomatosis with polyangiitis, formerly known as Churg-Strauss syndrome. Learn more about this study.
Last Updated April 23, 2014